# Network Biology of Protein Lipidation & Therapeutic Insights
> Explore myristoylation, palmitoylation, and prenylation mechanisms. Learn how protein lipidation impacts cellular signaling and drug discovery targets.

Tags: protein-lipidation, biochemistry, cell-signaling, systems-biology, pharmacology, molecular-biology, proteomics
## Network Biology of Protein Lipidation
- Overview of lipid-modified proteomes and systems-level applications in cellular signaling.

## Defining the Lipid-Modified Proteome
- **Definition:** Covalent attachment of lipid moieties to amino acid residues.
- **Functions:** Membrane anchoring, trafficking, protein stability, and PPI mediation.

## Taxonomy of Protein Lipidation
- **N-Myristoylation:** Myristate (C14:0) on N-term Glycine; irreversible.
- **S-Palmitoylation:** Palmitate (C16:0) on internal Cysteine; reversible.
- **Prenylation:** Farnesyl (C15) or Geranylgeranyl (C20) on C-term Cysteine (CaaX box).
- **GPI Anchors:** Phosphatidylinositol glycan at the C-terminus.

## The Dynamic Palmitoylation Cycle
- Managed by 'Writers' (ZDHHC family PATs) and 'Erasers' (APTs/ABHDs).
- Acts as a rapid regulatory switch similar to phosphorylation.

## Enzyme-Substrate Architectures
- 23 mammalian ZDHHCs serve as 'hubs' in dense interaction networks.
- Substrate specificity displays high redundancy for system robustness.

## Mechanism of Prenylation: The CaaX Box
- Sequential processing: Prenylation (FTase/GGTase) → Cleavage (-aaX) → Carboxyl-methylation (ICMT).

## Membrane Compartmentalization & Trafficking
- Lipid modifications act as 'zip codes' for kinetic trapping.
- Typical distribution: Plasma Membrane (45%), Golgi (25%), Endosomes (15%), Others (15%).

## Case Study: The Ras Superfamily
- **H-Ras/N-Ras:** Farnesylated and Palmitoylated.
- **K-Ras:** Farnesylated with a polybasic domain.
- **Impact:** 30% of human cancers involve Ras mutations linked to these anchors.

## Multi-Omics and Experimental Tools
- **Detection:** Acyl-Biotin Exchange (ABE) and bioorthogonal 'Click' chemistry (e.g., Alk-16).
- **Growth:** Protein count identified has grown from ~50 pre-2005 to ~5000 in current datasets.

## Applications: Drug Discovery Targets
- **FTIs:** Developed for Ras-cancers and Progeria (Lonafarnib).
- **NMT Inhibitors:** Targets for fungal and malaria infections.
- **ZDHHC Inhibitors:** Emerging treatments for epilepsy and specific cancers.

## Future Directions
- Deciphering the 'Palmitoylation Code'.
- Development of isoform-specific inhibitors for clinical use.
---
This presentation was created with [Bobr AI](https://bobr.ai) — an AI presentation generator.